Neuronal TGase (TG6) ELISA

ZediXclusive TG6-ab ELISA (IgA)


Neuronal transglutaminase (TG6) ELISA IgA

Order
Quantity
Price
Status
1 Kit/96 wells 520 € available


Documents
Art. No. E103
Background info The TG6-ab ELISA (IgA) kit with the Zedira product number E103 is the revised version of kit TG6-ab ELISA (IgA) with the product number E003.

Autoantibodies directed against neuronal transglutaminase (TG6) may occur in the sera of patients suffering from neurological disorders like e.g. ataxia, neuropathy, cerebral pulsy or stiffperson syndrome.
Autoantibodies to TG6 can be found in addition to TG2-autoantibodies in celiac patients, but were also found in TG2-autoantibody negative sera and in sera from patients without enteropathy (non-celiac patients). Therefore antibodies to TG6 may develop independent from celiac disease.
Assay principle The wells of the solid phase are coated with TG6.
1st reaction: TG6-specific antibodies present in the sample bind to the immobilised antigen, forming the antigen-antibody complex.
2nd reaction: A second antibody, directed at human IgA antibodies and labeled with horse-radish peroxidase (HRP), binds to the complex.
3rd reaction: The enzyme-labelled complex converts a substrate into a blue product. Samples containing IgA antibodies against TG6 develop the blue colour, whereas samples without these antibodies remain colourless.
Intended use The present Enzyme-Linked Immuno Sorbent Assay (ELISA) is intended for the quantitative or qualitative determination of IgA antibodies in human serum, directed against TG6. The immobilised antigen is a highly purified preparation of human recombinant TG6. The test is fast (incubation time 30 / 30 / 30 minutes) and flexible (divisible solid phase, ready-to-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control check the assay performance.
Storage Store kit at 2 - 8°C. It is stable up to the expiry date stated on the label of the box. Do not use kit beyond its expiry date.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy